Join
Live feed
·
PRReleasevia Quantisnow
Timber Pharmaceuticals Inc. logo

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

ByQuantisnow·Wall Street's wire, on your screen.
TMBR· Timber Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TMBR (Timber Pharmaceuticals Inc.) and more on Quantisnow.